Exemplar studies in assessing the value of innovative medical devices for adoption within the NHS

评估 NHS 内采用的创新医疗设备价值的范例研究

基本信息

批准号：
EP/F037775/1
负责人：
Stephen Morgan
金额：
$ 12.74万
依托单位：
University of Nottingham
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2008
资助国家：
英国
起止时间：
2008 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=EP%2FF037775%2F1
关键词：
Exemplar studies assessing value innovative

项目摘要

This 11 month collaborative proposal between the Multidisciplinary Assessment of Technology Centre for Healthcare (MATCH) and the NHS aims to determine how health economic approaches can be used most effectively to assess value for the purposes of procurement and innovation assessment decision-making. The research is based on health economic study of a set of exemplars that have been chosen to cover three important classes of device-related purchases that are encountered by the Purchasing and Supply Agency (PASA): incremental technologies, disruptive technologies and 'packages of care', A further three exemplars are medical device innovations that the National Innovation Centre (NIC) wishes to evaluate. Methods we will employ include short run versions of cost-utility evaluations based on Quality-of-life Adjusted Life Years that are used by health technology assessment bodies like the National Institute for Heath and Clinical Excellence. Alternatives we will investigate include cost-benefit 'Willingness to Pay' methods. Most importantly, both kinds of health economic evaluation method aim to balance patient benefit or preference against cost when determining the value of an innovation.The context for this research is the problem faced by the National Health Service in making appropriate decisions about the purchase of innovative healthcare devices in an environment of severe budgetary constraints and alongside ambitious national and regional healthcare priorities. Whilst is it clear that 'value for money' should always include evidence of clinical effectiveness relating to the choices made, without a full integration of patient outcomes and/or clinical opinion into the procurement framework, adoption of innovations can easily become a victim of purchase at lowest cost. Alternatively, innovations that have been identified as improvers of healthcare may not be judged to be affordable, with a danger of wasting the huge resources being put into healthcare R&D. To ensure national relevance, the results of the studies will be disseminated across the NHS Institute for Innovation and Improvement, the NHS Collaborative Procurement Hubs, the Centre for Evidence-based Procurement, and the medical devices industry through the MATCH partnership. Consultation with the Association of British Healthcare Industries (ABHI) at the beginning of the project and their invitation to dissemination events will ensure additional industry engagement. Deliverables will include a report of the exemplar studies and national dissemination by means of a PASA/NIC workshop and a European Health Technology Assessment conference presentation. The work is strongly aligned to the objectives of the Healthcare Industries Task Force (HITF) that is being enacted by its Strategic Implementation Group.The proposal will also answer questions about approaches to innovation that are being raised in ongoing 'Promoting Disruptive Healthcare in the NHS' Steering Group meetings led by the Healthcare Engineering Group at Loughborough University and including representatives from both PASA and NIC, the ABHI, HaCIRIC and MATCH. It is anticipated that these relationships will be preserved and enhanced during the work proposed here. For MATCH, there is a unique opportunity to work with both sides of the innovation/procurement puzzle and to provide some underpinning, common view of, value. This is probably the first time that such an opportunity has arisen in the UK. Moreover, it would be impossible to conceive of this type of project in isolation - it would cost considerably more to conduct the whole programme as a piece of stand-alone research, but the value is effectively doubled by drawing on core MATCH funds and the partnership funding stream.

这个11个月的合作提案是对医疗保健技术中心（MATED）和NHS的多学科评估之间的合作提议，旨在确定如何最有效地使用健康经济方法来评估价值，以进行采购和创新评估决策。这项研究基于对一系列典范的健康经济研究，这些典范已被选为购买和供应机构（PASA）遇到的三个重要类别的与设备相关的购买：增量技术，破坏性技术和“护理包装”，另外三个典范是国家内部intovation Innovation Innovation Center（Nic Innovation Center（NIC）的愿望，以评估Nic Entovation Innovation Center（Nic）。我们将采用的方法包括基于生活质量调整的生活年份的成本效用评估的短期版本，这些终身评估机构（如国立卫生和临床卓越研究所）所使用。我们将调查的替代方案包括成本效益的“愿意支付”方法。最重要的是，两种健康经济评估方法旨在在确定创新价值时平衡患者的利益或偏爱与成本。这项研究的背景是国家卫生服务局面临的问题，即在严重的预算约束和雄心勃勃的国家医疗保健方面做出有关购买Innovative医疗保健设备的适当决定。虽然很明显，“物有所值”应始终包括与选择的临床有效性的证据，而无需将患者结果和/或临床意见完全整合到采购框架中，但采用创新的受害者很容易以最低的成本成为购买的受害者。另外，已被确定为医疗保健改进的创新可能不会被判断为负担得起，而危险将巨大的资源浪费在医疗保健研发中。为了确保国家的相关性，研究结果将在NHS创新与改进研究所，NHS合作采购中心，基于证据的采购中心以及通过比赛合作伙伴关系中传播。在项目开始时与英国医疗保健行业协会（ABHI）协商及其邀请传播活动的邀请将确保额外的行业参与。可交付成果将包括示例研究和国家传播的报告，并通过PASA/NIC研讨会和欧洲健康技术评估会议演讲。这项工作与由其战略实施小组实施的医疗保健行业工作队（HITF）的目标密切相符。该提案还将回答有关在NHS促进NHS的指导小组会议中，由NHS的指导集团和包括Lofferough大学的NIC组成的NHS指导小组会议促进的颠覆性医疗保健的问题还将回答有关创新方法的问题。匹配。预计在此处提出的工作期间，这些关系将得到保留和增强。对于比赛，有一个独特的机会与创新/采购难题的两面合作，并提供一些基础，共同的价值观点。这可能是英国第一次出现这种机会。此外，不可能孤立地想象这类项目 - 将整个程序作为一项独立研究的成本要高得多，但是通过绘制核心比赛资金和合伙企业资金流的绘制，该价值有效地翻了一番。